Results 51 to 60 of about 31,650 (136)

Peptide‐directed nanovehicles enabling tumor‐selective ROS amplification and antitumor immunity

VIEW, EarlyView.
Cancer cells are vulnerable to oxidative stress, yet exploit immune tolerance to escape destruction. In contrast, their metabolic profile is markedly altered to support rapid proliferation, accompanied by elevated production of reactive oxygen species (ROS).
Manuela Calin, Galyna Bila, Ileana Manduteanu, Rostyslav Bilyy   +3 more
wiley   +1 more source

Nanobodies as next‐generation targeting platforms: From discovery technologies to translational biomedicine

VIEW, EarlyView.
Nanobodies, derived from the variable domains of camelid heavy‐chain‐only antibodies, have emerged as transformative biomedical tools due to their nanoscale size, exceptional stability, and unique capacity to recognize cryptic epitopes. This review provides a comprehensive overview of the field, outlining the structural and biochemical features of ...
Zhenrui Ye, Xianyang Li, Meixiao Zhan
wiley   +1 more source

Oral Mucositis in Oncopediatric Patients: MTX and MMP‐1, MMP‐8, MMP‐13 Gene Polymorphisms

Oral Diseases, EarlyView.
ABSTRACT Background This study investigates the association between single‐nucleotide polymorphisms (SNPs) in the MMP‐1, MMP‐8, and MMP‐13 genes and the risk of oral mucositis development in paediatric patients with leukaemia and lymphoma who are undergoing methotrexate (MTX) treatment.
Nicole Januário Ribeiro, Larissa Helena Tissi, Mateus Tissot Escobar, Ana Maria Gondim Valença, Ricardo Lehtonen Rodrigues Souza, Naila Francis Paulo de Oliveira, Maria Cristina Leme Godoy Santos   +6 more
wiley   +1 more source

Impaired hematopoiesis affects apheresis and CAR T‐cell product composition and treatment response

Transfusion, EarlyView.
Abstract Background Chimeric antigen receptor (CAR) T‐cell therapy has transformed the treatment of hematologic malignancies, but its success depends on obtaining sufficient CD3+ T‐cell yields during leukapheresis. This can be difficult in heavily pretreated patients, who often show leukopenia and reduced T‐cell fitness.
Hanna Kuhn, Felix Korell, Angela Hückelhoven‐Krauss, Brigitte Neuber, Miriam Stenzinger, Anita Ludwig‐Husemann, Maria‐Luisa Schubert, Patrick Derigs, Kiavasch Farid, Tim Sauer, Sandra Sauer, Carsten Müller‐Tidow, Peter Dreger, Michael Schmitt, Anita Schmitt   +14 more
wiley   +1 more source

Clinical Insights Into Hypercalcemia of Malignancy in Childhood

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT Hypercalcemia of malignancy (HCM) is a rare but life‐threatening metabolic emergency in children that occurs in less than 1% of pediatric cancer cases, with a reported incidence ranging from 0.4% to 1.0% across different studies. While it is observed in 10%–20% of adult malignancies, pediatric HCM remains relatively uncommon.
Hüseyin Anıl Korkmaz
wiley   +1 more source

Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials

Molecular Therapy: Methods & Clinical Development, 2020
Tisagenlecleucel is a CD19-specific chimeric antigen receptor (CAR)-T cell therapy approved for patients aged ≤25 years with relapsed or refractory B cell precursor acute lymphoblastic leukemia (B-ALL) and adults with relapsed or refractory diffuse large
Seshu Tyagarajan, Tom Spencer, Jonathan Smith   +2 more
doaj   +1 more source

Two Faces of NOTCH1 in Childhood Lymphoblastic T‐Cell Neoplasia: Prognostic Divergence of Mutational and Structural Aberrations

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
ABSTRACT In pediatric patients, T‐cell lymphoblastic lymphoma (T‐LBL) survival exceeds 80%. Relapse remains associated with limited curative options. Frontline treatment is largely extrapolated from T‐cell acute lymphoblastic leukemia (T‐ALL) treatment, reflecting the ongoing debate, whether both entities represent distinct diseases or variants within ...
Marie C. Heider, Amelie Alfert, Marc Hotfilder, Birgit Burkardt, Marcel te Vrugt   +4 more
wiley   +1 more source

Leveraging Macrophage Metabolic Reprogramming for Enhanced Anti‐Tumor Immunity

Advanced Science, Volume 13, Issue 33, 15 June 2026.
Tumor‐associated macrophages (TAMs) are key regulators of the tumor microenvironment (TME), with their metabolic states playing a critical role in tumor progression or regression. This review summarizes current understanding of TAM metabolic plasticity alongside cutting‐edge bioengineering innovations, outlining a roadmap for transforming the ...
Zhiyun Liu, Lingyao Zeng, Xulin Gan, Yilin Zhou, Han Shen, Dan Wu, Xin Shou, Minmin Jiang, Liyun Shi   +8 more
wiley   +1 more source

Isolated Central Nervous System Presentation of Early T-Cell Precursor Acute Lymphoblastic Leukemia/Lymphoma: A Rare Case of Exclusive Brain Involvement

Case Reports in Hematology
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) is a high-risk and biologically distinct subset of T-cell acute lymphoblastic leukemia, typically characterized by leukemic involvement of bone marrow, peripheral blood, and ...
Violet O. Swart, Behyar Zoghi
doaj   +1 more source

Oral Lesions Developed in Post‐Hematopoietic Stem Cell Transplant Patients and the Role of Cryogun Cryotherapy

Clinical and Experimental Dental Research, Volume 12, Issue 3, June 2026.
ABSTRACT Objective To investigate the development of oral premalignant and malignant lesions as a major long‐term complication following hematopoietic stem cell transplantation. Methods This single‐center retrospective study identified 17 patients who developed 26 pathology‐confirmed oral premalignant and malignant lesions after hematopoietic stem cell
Pei Hsuan Lu, Kelly Yi Ping Liu, Samson P. Ng, Catherine F. Poh   +3 more
wiley   +1 more source